Immune stimulation--a class effect of phosphorothioate oligodeoxynucleotides in rodents

Author(s): Monteith DK, Henry SP, Howard RB, Flournoy S, Levin AA, et al.

Abstract

Treatment of rodents with phosphorothioate oligodeoxynucleotides induces a form of immune stimulation characterized by splenomegaly, lymphoid hyperplasia, hypergammaglobulinemia and mixed mononuclear cellular infiltrates in numerous tissues. Immune stimulation was evaluated in mice with in vivo and in vitro studies using a review of historical data and specific in vivo and in vitro studies. All phosphorothioate oligodeoxynucleotides evaluated induced splenomegaly and B-lymphocyte proliferation. Splenomegaly and B-lymphocyte proliferation increased with dose or concentration of oligodeoxynucleotide. Splenomegaly appeared to occur, at least in part, as a result of stimulation of B-lymphocyte proliferation. There were differences with respect to degree or potency of immune stimulation by different oligodeoxynucleotides. The rank order potencies for B-lymphocyte proliferation in vitro and splenomegaly correlated well for the oligodeoxynucleotides tested. Particular oligodeoxynucleotide sequence motifs or palindromes have been demonstrated to affect in vitro cell proliferation. Inclusion of a 5'-AACGTT-3' palindrome in a phosphorothioate oligodeoxynucleotide sequence significantly enhanced the potency. While inclusion of this palindrome or a CpG motif alone may contribute to the immune stimulation, these palindromes and motifs were clearly not the sole factor required for immune stimulation. Several phosphorothioate oligodeoxynucleotides that did not contain a CpG motif still induced immune stimulation in mice. The immune stimulation induced by phosphorothioate oligodeoxynucleotides was an effect of this class of compounds to which rodents are acutely sensitive.

Similar Articles

Role of Interferons in the Development of Diagnostics, Vaccines, and Therapy for Tuberculosis

Author(s): Chin KL, Anis FZ, Sarmiento ME, Norazmi MN, Acosta A, et al.

Role of Type I and II Interferons in Colorectal Cancer and Melanoma

Author(s): Di Franco S, Turdo A, Todaro M, Stassi G

Innate immune response induced by gene delivery vectors

Author(s): Sakurai H, Kawabata K, Sakurai F, Nakagawa S, Mizuguchi H, et al.

Analysis of Pro-inflammatory Cytokine and Type II Interferon Induction by Nanoparticles

Author(s): Potter TM, Neun BW, Rodriguez JC, Ilinskaya AN, Dobrovolskaia MA, et al.

More than 70 years of pyrogen detection: Current state and future perspectives

Author(s): Fennrich S, Hennig U, Toliashvili L, Schlensak C, Wendel HP, et al.

Evidence for the detection of non-endotoxin pyrogens by the whole blood monocyte activation test

Author(s): Hasiwa N, Daneshian M, Bruegger P, Fennrich S, Hochadel A, et al.

International validation of novel pyrogen tests based on human monocytoid cells

Author(s): Hoffmann S, Peterbauer A, Schindler S, Fennrich S, Poole S, et al.

Nucleic acids as therapeutic agents

Author(s): Alvarez-Salas LM

Aptamers as therapeutics

Author(s): Keefe AD, Pai S, Ellington A

5'-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I

Author(s): Schmidt A, Schwerd T, Hamm W, Hellmuth JC, Cui S, et al.